SCHEMBL2583691

SCHEMBL2583691

COc1ccc(-c2ccc3c(O)c(CNCC(=O)O)c(=O)n(C)c3n2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 2/20 0.42
CASP3 P42574 1/20 0.42
SENP8 Q96LD8 1/20 0.42
SENP7 Q9BQF6 1/20 0.42
SENP6 Q9GZR1 1/20 0.42
PARP1 P09874 1/20 0.40
GABRP O00591 1/20 0.40
GABRD O14764 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
GABRA1 P14867 1/20 0.40
ALOX15 P16050 1/20 0.40
GABRB1 P18505 1/20 0.40
GABRG2 P18507 1/20 0.40
GABRB3 P28472 1/20 0.40
GABRA5 P31644 1/20 0.40
CYP2C19 P33261 1/20 0.40
GABRA3 P34903 1/20 0.40
GABRA2 P47869 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2582477 0.89 GRM2 (0.39) HIF1AEGLN1TMIGD3KDM5BALDH1A1
SCHEMBL2583694 0.82 HIF1A (0.63) HIF1AEGLN1
SCHEMBL2578322 0.78 ERCC1 (0.43) HIF1ACYP1A2CYP2C9CYP2C19HSD17B10
SCHEMBL12101602 0.76 HIF1A (0.53) HIF1AEGLN1ALDH1A1
SCHEMBL2582478 0.70 EGLN1 (0.56) HIF1AEGLN1
SCHEMBL336504 0.67 EGLN1 (0.65) HIF1AEGLN1
SCHEMBL19240108 0.66 EGLN1 (0.71) EGLN1ALDH1A1LMNAHTT
SCHEMBL20109778 0.65 EGLN1 (0.74) EGLN1
SCHEMBL20109769 0.65 EGLN1 (0.60) EGLN1KDM5B
SCHEMBL1807496 0.64 MEN1 (0.61) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8048892-B2 Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2011-11-01 US disclosed
US-20090111806-A1 Azaquinolone based compounds exhibiting prolyl hydroxylase Inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2009-04-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111806-A1 Azaquinolone based compounds exhibiting prolyl hydroxylase Inhibitory activity, compositions, and uses thereof EGLN3, EGLN2, HIF1AN HIF1A 6/4885CASP3 3131/4885SENP8 2811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.